Biogen Q3 2026 earnings

BIIB · 2026-10-28 06:07 BMO ET · 8-K on SEC

Revenue growth accelerates to 11% YoY with the first full quarter contribution from the Apellis acquisition driving a 49% increase in the Growth Portfolio.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$2.80B+11.0%+3.4%Ex. 99.1, Financial Highlights
EPS (GAAP)$(0.14)-104.0%-0.80Ex. 99.1, Financial Highlights
EPS (adjusted)$2.62-46.0%-0.98Ex. 99.1, Financial Highlights
Net income$(20.6M)-104.4%-0.80Ex. 99.1, Income Statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Growth Portfolio$1.26B+49.0%63%Includes first full quarter contribution from Apellis products
Legacy MS Portfolio$919M-13.0%33%Includes TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI
Rare disease$676M+27.0%24%Includes SPINRAZA, SKYCLARYS and QALSODY
Specialized immunology$243MN/A9%Includes EMPAVELI and SYFOVRE
Biosimilars$166M-16.0%6%—

Margins and costs

  • Gross margin 20.0% (prior 20.0%, change 0.0 pp)
  • Operating expenses $1,287M (+32.0% YoY)
  • One-offs in the quarter $284M acquired IPR&D, upfront and milestone expense (RayThera); $137M GAAP other expense (net interest, equity losses, litigation); $91M Non-GAAP other expense (net interest)
  • Effective tax rate N/A (GAAP loss)
  • Non-GAAP bridge Adds back acquired IPR&D, upfront and milestone expense ($284M), amortization and impairment of acquired intangible assets, and other non-cash items; excludes litigation and restructuring.

KPIs

MetricActualPrior quarterPrior yearChange
Free cash flow$600M$408M$1,226M+47%
Weighted average diluted shares149M149M147.1M+1%
Cash and cash equivalents$1.30B$1.30B$1.28B+1%

Guidance

MetricGuidePrior guideChange
Full year 2026 Non-GAAP diluted EPS$12.20 to $13.00$12.00 to $13.00Raised lower end by $0.20
Full year 2026 Non-GAAP R&D and SG&A$4.95B$2.65B-$2.70B (H2 only)Full year guidance provided

What drove it

  • Revenue story Total revenue grew 11% YoY driven by a 49% increase in the Growth Portfolio (including first full quarter contribution from Apellis products) and a 60% increase in Alzheimer's collaboration revenue, partially offset by a 13% decline in the Legacy MS Portfolio and a 16% decline in Biosimilars revenue.
  • EPS story GAAP EPS turned negative to $(0.14) driven by $284M of acquired IPR&D, upfront and milestone expense; Non-GAAP EPS declined 46% YoY due to the same acquisition charges and lower revenue.
  • One-off check $284M acquired IPR&D, upfront and milestone expense (RayThera) and $91M Non-GAAP other expense (net interest) related to the Apellis acquisition.

The good

  • Growth Portfolio revenue grew 49% YoY to $1.26B, representing 63% of Core Pharmaceutical revenue
  • Alzheimer's collaboration revenue grew 60% YoY to $68M
  • Free cash flow of $600M

The bad

  • Legacy MS Portfolio revenue declined 13% YoY to $919M
  • Biosimilars revenue declined 16% YoY to $166M
  • Non-GAAP diluted EPS declined 46% YoY to $2.62

The ugly

  • none

Open questions

  • The filing does not provide the specific dollar amount of the $0.85 dilution to Non-GAAP diluted EPS for full year 2026 mentioned in the Q2 release.
  • The filing does not provide a reconciliation of the updated full year 2026 Non-GAAP diluted EPS guidance range to GAAP.
Full release

Earnings: BIIB — filed 2026-10-28

Biogen Inc. (BIIB) · Form 8-K, Item 2.02 · Filed · SEC filing

Press Release

Cambridge, Mass. – October 28, 2026

Biogen Reports Third Quarter 2026 Results

• Third quarter 2026 total revenue of $2.8 billion increased 11% year-over-year; Growth Portfolio¹ revenue of $1.26 billion, increased 49% year-over-year, representing 63% of Core Pharmaceutical² revenue, including a strong first full quarter contribution from the acquired Apellis products

• GAAP diluted EPS of $(0.14) driven primarily by transaction-related charges; Non-GAAP diluted EPS of $2.62, reflecting $284 million of acquired IPR&D, upfront and milestone expense

• Third quarter results include strong operating performance from the legacy Apellis portfolio reflecting successful ongoing integration execution

• Full year 2026 Non-GAAP diluted EPS guidance: Biogen raises the lower end of the reported range to $12.20 to $13.00 from $12.00 to $13.00 reflecting ongoing business strength and Apellis dilution favorability

Biogen Inc. (Nasdaq: BIIB) today reported third quarter 2026 financial results.

“Our third quarter results demonstrate that Biogen has returned to growth. We’re seeing the strength of our Growth Portfolio – including the first full quarter of results from Apellis products – which helped drive double-digit revenue growth and an approximately 50% year-over-year increase from our growth products,” said President and Chief Executive Officer Christopher A. Viehbacher. “With multiple Phase 3 readouts expected over the next 12 months, we are positioned to further strengthen our long-term growth profile and create sustainable value for patients and shareholders."

Third Quarter 2026 Growth Portfolio In-Market Revenue Summary¹

Growth Portfolio includes EMPAVELI, QALSODY, SKYCLARYS, SPINRAZA, SYFOVRE, VUMERITY, ZURZUVAE, plus Biogen's 50% share of net revenue and cost of sales, including royalties, from the LEQEMBI Collaboration²

Core Pharmaceutical revenue includes product revenue excluding biosimilars revenue plus Biogen’s 50% share of net revenue and cost of sales, including royalties, from the LEQEMBI Collaboration³

Global in-market sales recorded by Eisai⁴

SYFOVRE and EMPAVELI were acquired as part of Biogen’s acquisition of Apellis, which closed in May 2026. Prior period revenue as reported in the Apellis Pharmaceuticals, Inc. Q3 2025 10-Q¹

Financial Highlights

Third quarter 2026 GAAP and Non-GAAP diluted EPS include $284 million of acquired IPR&D, upfront and milestone expense, primarily related to the acquisition of RayThera Inc. as compared to $2 million in the third quarter of 2025.

Note: Percent changes represented as favorable/(unfavorable) versus the prior year period. N/A = not applicable.

*

Percentage changes in revenue growth at constant currency (CC) are presented excluding the impact of changes in foreign currency exchange rates and hedging gains or losses. Foreign currency revenue values are converted into U.S. Dollars using the exchange rates from the end of the previous calendar year.

A reconciliation of GAAP to Non-GAAP financial measures can be found in Table 4 at the end of this news release.

Revenue Summary

Note: Percent changes represented as favorable/(unfavorable) versus the prior year period. Numbers may not foot or recalculate due to rounding.

(1)

Multiple sclerosis includes TECFIDERA®, VUMERITY®, AVONEX®, PLEGRIDY® and TYSABRI®

(2)

Rare disease includes SPINRAZA®, SKYCLARYS® and QALSODY®

(3)

Specialized immunology includes EMPAVELI® and SYFOVRE®

(4)

Other includes ZURZUVAE®

(5)

Includes Biogen’s 50% share of net revenue and cost of sales, including royalties, from the LEQEMBI® Collaboration

Expense Summary

Note: Percent changes represented as favorable/(unfavorable) versus the prior year period

IPR&D = in-process R&D; NMF = no meaningful figure

*

Excluding amortization and impairment of acquired intangible assets²

• The increase in third quarter 2026 GAAP cost of sales as a percentage of total revenue was driven primarily by higher amortization costs associated with the acquired inventory fair value step-up related to the Reata and Apellis acquisitions, as well as product mix, partially offset by a litigation matter in the third quarter of 2025. The increase in third quarter 2026 Non-GAAP cost of sales as a percentage of total revenue was driven primarily by product mix.

• The increase in third quarter 2026 GAAP and Non-GAAP R&D expense was driven by higher spend on clinical trials, including felzartamab, salanersen and litifilimab, as well as the inclusion of operating expenses from Apellis, and a reduction in R&D funding received from Royalty Pharma.

• The increase in third quarter 2026 GAAP and Non-GAAP SG&A was primarily due to the inclusion of the commercial and management operations of Apellis and an increase in operational spending on sales and marketing activities in support of our U.S. and international product launches.

• Third quarter 2026 GAAP and Non-GAAP acquired IPR&D, upfront and milestone expense was $284 million, primarily related to the acquisition of RayThera Inc.

Other Financial Highlights

• Third quarter 2026 GAAP and Non-GAAP collaboration profit sharing was a net expense of approximately $78 million, which includes approximately $49 million related to Biogen’s collaboration with Samsung Bioepis, and approximately $29 million related to Biogen’s collaboration with Supernus Pharmaceuticals, Inc. for the commercialization of ZURZUVAE in the U.S.

• Third quarter 2026 GAAP other expense was approximately $137 million driven by net interest expense, losses on our equity investments, and higher litigation expenses. Third quarter 2026 Non-GAAP other expense was approximately $91 million primarily driven by net interest expense due to the Apellis acquisition.

• ... (truncated)y the non-deductible IPR&D charge related to the RayThera stock acquisition.

Financial Position and Cash Flows

• Third quarter 2026 net cash flow from operations was approximately $641 million. Capital expenditures were approximately $40 million, and free cash flow, a Non-GAAP financial measure defined as net cash flow from operations less capital expenditures, was approximately $600 million.

• As of September 30, 2026, Biogen had cash and cash equivalents totaling approximately $1.3 billion and approximately $7.7 billion in total debt, resulting in net debt of approximately $6.4 billion.

• For the third quarter of 2026, the Company’s weighted average diluted shares were approximately 148 million and 149 million, used to calculate the Company's GAAP and Non-GAAP diluted EPS, respectively. All unvested equity-based awards are antidilutive for GAAP due to reporting a GAAP net loss for the third quarter 2026.

The Company is advancing multiple potential growth drivers with registrational readouts expected over the next 12 months

• The Company expects to announce top line data from both TOPAZ-1 and TOPAZ-2 Phase 3 studies, evaluating litifilimab in SLE, in the first half of December 2026.

• Additional Phase 3 readouts expected for litifilimab in CLE, felzartamab in antibody mediated rejection in the first half of 2027 and zorevunersen in Dravet syndrome in the third quarter of 2027.³

Full Year 2026 Financial Guidance

Biogen is raising the lower end of the reported full year 2026 Non-GAAP diluted EPS guidance range to reflect ongoing business strength and Apellis dilution favorability. Full year 2026 Non-GAAP diluted EPS range is expected as follows:

Full year total revenue is expected to increase by a mid-single digit percentage for 2026 as compared to 2025 driven by continued growth from our Growth Portfolio.

Biogen expects combined Non-GAAP R&D expense and Non-GAAP SG&A expense to be approximately $4.95 billion for the full year 2026.

This guidance also assumes that foreign exchange rates as of October 23, 2026, will remain in effect for the remainder of the year, net of hedging activities.

Other than the acquired IPR&D, upfront and milestone impact expressly stated above, this financial guidance does not include any other potential future acquired IPR&D, upfront and milestone charges, impact from potential acquisitions or business development transactions or pending and future litigation or any impact of potential healthcare reform, as all are difficult to predict. Other important financial considerations will be provided on the conference call and webcast.

Biogen may incur charges, realize gains or losses, or experience other events or circumstances in 2026 that could cause any of these assumptions and expectations to change and/or actual results to vary from this financial guidance.

Biogen does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the Company is unable without unreasonable effort to predict with reasonable certainty the financial impact of items such as the transaction, integration, and certain other costs related to acquisitions or large business development transactions; unusual gains and losses; potential future asset impairments; gains and losses from equity security investments; and the ultimate outcome of pending or future litigation. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the Company is unable to address the significance of the unavailable information, which could be material to future results.

Conference Call and Webcast

The Company’s earnings conference call for the third quarter will be broadcast via the internet at 8:30 a.m. ET on October 28, 2026 and will be accessible through the Investors section of Biogen’s website, www.biogen.com. Supplemental information in the form of a slide presentation is also accessible at the same location on the internet and will be subsequently available on the website for at least 90 days.⁴

About Biogen

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients' lives and to create value for shareholders and our communities.

We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

Biogen Safe Harbor

Financial statements

Income Statement

Financial Highlights (in millions)

Q3 '26Q3 '25△r (CC*)
Total Revenue ($ in millions)2,8042,53511.0%10.0%
GAAP diluted EPS-0.143.17-104.0%N/A
Non-GAAP diluted EPS2.624.81-46.0%N/A

Income Statement

Revenue Summary (in millions)

Q3 '26Q3 '25△r (CC*)
Multiple sclerosis (MS) product revenue(1)9191,062-13.0%-13.0%
Rare disease revenue(2)67653327.0%27.0%
Specialized immunology revenue(3)243$——%—%
Biosimilars revenue166197-16.0%-19.0%
Other product revenue(4)845553.0%53.0%
Total product revenue2,0891,84713.0%13.0%
Revenue from anti-CD20 therapeutic programs4974941.0%1.0%
Alzheimer's collaboration revenue(5)684360.0%60.0%
Contract manufacturing, royalty and other revenue150151-1.0%-1.0%
Total revenue2,8042,53511.0%10.0%

Income Statement

Expense Summary (in millions)

Q3 '26Q3 '25△
GAAP cost of sales*748674-11.0%
% of Total Revenue27.0%27.0%
Non-GAAP cost of sales*553510-8.0%
% of Total Revenue20.0%20.0%
GAAP R&D expense574436-32.0%
Non-GAAP R&D expense567432-31.0%
GAAP SG&A expense752595-26.0%
Non-GAAP SG&A expense730592-23.0%
GAAP and Non-GAAP acquired IPR&D, upfront and milestone expense2842NMF

Income Statement

For the Three Months Ended September 30, — (unaudited, in millions, except per share amounts)

For the Three Months Ended September 30, – 2026For the Three Months Ended September 30, – 2025For the Nine Months Ended September 30, – 2026For the Nine Months Ended September 30, – 2025
Revenue:Product revenue, net2,088.71,846.95,757.45,452.1
Revenue:Revenue from anti-CD20 therapeutic programs497.3493.91,429.91,339.4
Revenue:Alzheimer's collaboration revenue68.442.7191.6130.6
Revenue:Contract manufacturing, royalty and other revenue149.7151.2639689.1
Revenue:Total revenue2,804.12,534.78,017.97,611.2
Cost and expense:Cost of sales, excluding amortization and impairment of acquired intangible assets748.4674.42,186.31,908.7
Cost and expense:Research and development574436.11,642.61,269.2
Cost and expense:Acquired in-process research and development, upfront and milestone expense283.82.1481.8249.4
Cost and expense:Selling, general and administrative752594.82,0691,751.1
Cost and expense:Amortization and impairment of acquired intangible assets172.8135.7477.5378.4
Cost and expense:Collaboration profit sharing/(loss reimbursement)77.887.2220.8220.3
Cost and expense:(Gain) loss on fair value remeasurement of contingent consideration0.45.623.428.4
Cost and expense:Restructuring charges66.57.4239.842
Cost and expense:Other (income) expense, net137.434.1175.6151.2
Cost and expense:Total cost and expense2,813.11,977.47,516.85,998.7
Cost and expense:(Loss) Income before income tax (benefit) expense-9557.3501.11,612.5
Cost and expense:Income tax (benefit) expense11.690.8104.7270.7
Cost and expense:Net (loss) income attributable to Biogen Inc.-20.6466.5396.41,341.8
Net (loss) income per share:Basic earnings per share attributable to Biogen Inc.-0.143.182.699.16
Net (loss) income per share:Diluted earnings per share attributable to Biogen Inc.-0.143.172.669.14
Weighted-average shares used in calculating:Basic earnings per share attributable to Biogen Inc.147.8146.6147.5146.4
Weighted-average shares used in calculating:Diluted earnings per share attributable to Biogen Inc.147.8147.1148.9146.8

Income Statement

For the Three Months Ended September 30, — Total Revenue

For the Three Months Ended September 30, – 2026For the Three Months Ended September 30, – 2025For the Nine Months Ended September 30, – 2026For the Nine Months Ended September 30, – 2025
Product revenue, net2,088.71,846.95,757.45,452.1
Royalty revenue on sales of OCREVUS369.9386.41,068.51,029
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO118.3101338.7292.4
Other revenue from anti-CD20 therapeutic programs9.16.522.718
Alzheimer's collaboration revenue68.442.7191.6130.6
Contract manufacturing, royalty and other revenue149.7151.2639689.1
Total revenue2,804.12,534.78,017.97,611.2

Income Statement

For the Three Months Ended September 30,

For the Three Months Ended September 30, – 2026For the Three Months Ended September 30, – 2025For the Nine Months Ended September 30, – 2026For the Nine Months Ended September 30, – 2025
Cost of Sales:Total cost of sales, GAAP748.4674.42,186.31,908.7
Cost of Sales:Less: litigation matter1.1104.33.4104.3
Cost of Sales:Less: amortization of inventory fair value step-up194.860408.1160.1
Cost of Sales:Total cost of sales, Non-GAAP552.5510.11,774.81,644.3
Research and Development Expense:Total research and development expense, GAAP574436.11,642.61,269.2
Research and Development Expense:Less: amortization of inventory fair value step-up92.9
Research and Development Expense:Less: acquisition-related transaction and integration costs4.94.9
Research and Development Expense:Less: restructuring charges and other cost saving initiatives24.38.217.1
Research and Development Expense:Total research and development expense, Non-GAAP567.1431.81,536.61,252.1
Selling, General and Administrative Expense:Total selling, general and administrative, GAAP752594.82,0691,751.1

Income Statement

Q3 2026 vs. Q3 2025

Q3 2026 vs. Q3 2025YTD 2026 vs. YTD 2025
Total Revenue:Revenue change, as reported10.65.3
Total Revenue:Less: impact of foreign currency translation and hedging gains / losses0.41.9
Total Revenue:Revenue change at constant currency10.23.4
Total Product Revenue:Revenue change, as reported13.15.6
Total Product Revenue:Less: impact of foreign currency translation and hedging gains / losses0.62.3
Total Product Revenue:Revenue change at constant currency12.53.3
Total MS Product Revenue:Revenue change, as reported-13.4-9
Total MS Product Revenue:Less: impact of foreign currency translation and hedging gains / losses-0.11.5
Total MS Product Revenue:Revenue change at constant currency-13.3-10.5
Total Rare Disease RevenueRevenue change, as reported26.811.9
Total Rare Disease RevenueLess: impact of foreign currency translation and hedging gains / losses-0.12.1
Total Rare Disease RevenueRevenue change at constant currency26.99.8
Total Biosimilars Product Revenue:Revenue change, as reported-15.7-10.4
Total Biosimilars Product Revenue:Less: impact of foreign currency translation and hedging gains / losses3.54.9
Total Biosimilars Product Revenue:Revenue change at constant currency-19.2-15.3
Total Other Product Revenue:Revenue change, as reported52.660.2
Total Other Product Revenue:Less: impact of foreign currency translation and hedging gains / losses0.2
Total Other Product Revenue:Revenue change at constant currency52.660
Total Revenue from Anti-CD20 Therapeutic Programs Revenue:Revenue change, as reported0.76.8
Total Revenue from Anti-CD20 Therapeutic Programs Revenue:Less: impact of foreign currency translation and hedging gains / losses0.1
Total Revenue from Anti-CD20 Therapeutic Programs Revenue:Revenue change at constant currency0.76.7
Total Revenue from Alzheimer's Collaboration Revenue:Revenue change, as reported60.246.7
Total Revenue from Alzheimer's Collaboration Revenue:Revenue change at constant currency60.246.7
Total Contract Manufacturing, Royalty and Other Revenue:Revenue change, as reported-1-7.3
Total Contract Manufacturing, Royalty and Other Revenue:Less: impact of foreign currency translation and hedging gains / losses0.13.4
Total Contract Manufacturing, Royalty and Other Revenue:Revenue change at constant currency-1.1-10.7

Balance Sheet

As of September 30, 2026 — (unaudited, in millions)

As of September 30, 2026As of December 31, 2025
ASSETSCash and cash equivalents1,303.93,008.5
ASSETSMarketable securities807.2
ASSETSAccounts receivable, net1,884.61,342.4
ASSETSDue from anti-CD20 therapeutic programs498524.6
ASSETSInventory2,224.42,168.1
ASSETSOther current assets1,673.51,123.3
ASSETSTotal current assets7,584.48,974.1
ASSETSMarketable securities431.9
ASSETSProperty, plant and equipment, net2,967.63,055.4
ASSETSOperating lease assets176.1265.4
ASSETSIntangible assets, net13,379.99,178.5
ASSETSGoodwill6,992.66,491.1
ASSETSDeferred tax asset293.7292.5
ASSETSInvestments and other assets659.8750.6
ASSETSTOTAL ASSETS32,054.129,439.5
LIABILITIES AND EQUITYCurrent portion of notes payable400
LIABILITIES AND EQUITYTaxes payable54.5114.8
LIABILITIES AND EQUITYAccounts payable430.3432
LIABILITIES AND EQUITYAccrued expenses and other3,013.62,802.6
LIABILITIES AND EQUITYTotal current liabilities3,898.43,349.4
LIABILITIES AND EQUITYNotes payable7,2926,286.8
LIABILITIES AND EQUITYDeferred tax liability1,163.9507.6
LIABILITIES AND EQUITYLong-term operating lease liabilities109.3290.4
LIABILITIES AND EQUITYOther long-term liabilities668.4748.5
LIABILITIES AND EQUITYTOTAL LIABILITIES13,13211,182.7

Cash Flow

For the Three Months Ended September 30,

For the Three Months Ended September 30, – 2026For the Three Months Ended September 30, – 2025For the Nine Months Ended September 30, – 2026For the Nine Months Ended September 30, – 2025
Cash Flow:Net cash provided by (used in) operating activities640.81,272.51,735.21,692.7
Cash Flow:Net cash provided by (used in) investing activities-222.1-35.1-4,270.8-139.4
Cash Flow:Net cash provided by (used in) financing activities-393.8-130.2858.4-164.9
Cash Flow:Net increase (decrease) in cash and cash equivalents24.91,107.2-1,677.21,388.4
Cash Flow:Net cash provided by (used in) operating activities640.81,272.51,735.21,692.7
Cash Flow:Less: Purchases of property, plant and equipment40.446.2132.5109.9
Cash Flow:Free cash flow600.41,226.31,602.71,582.8

This press release contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the PSLRA) with the intention of obtaining the benefits of the “Safe Harbor” provisions of the PSLRA. This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; the potential benefits, safety, and efficacy of our and our collaboration partners’ products and investigational therapies; the anticipated benefits and potential of investments or acquisitions; optimization of our cost structure including our "Fit for Growth" program; the goal of repositioning the company to create long-term growth; the impact from existing and potential tariffs and trade restrictions; productivity of our R&D pipeline, collaborations, and business development activities; our future financial and operating results; the costs and other anticipated financial impacts of the acquisition of Apellis including Biogen non-GAAP diluted EPS and non-GAAP diluted EPS growth, expected run rate synergies and the expected revenue growth for EMPAVELI and SYFOVRE following the acquisition of Apellis; and our full year 2026 financial guidance. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.

Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part.

We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: our substantial dependence on revenue from our products and other payments under licensing, collaboration, acquisition or divestiture agreements; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the drivers for growing our business; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are⁵ outside of our full control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology, including our incorporation of new technologies such as artificial intelligence into some of our processes; risks related to use of information technology systems and potential impacts of any breakdowns, interruptions, invasions, corruptions, data breaches, destructions and/or other cybersecurity incidents of our systems or those of connected and/or third-party systems; problems with our manufacturing capacity, including our ability to manufacture products efficiently or adequately address global bulk supply risks; risks relating to retaining management, personnel and other organizational changes, including our ability to attract, retain and motivate qualified individuals; risks related to the failure to comply with current and new legal and regulatory requirements, including judicial decisions, accounting standards, and tariff or trade restrictions; the risks of doing business internationally, including geopolitical tensions, acts of war and large-scale crises; risks relating to investment in our manufacturing capacity; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business, results of operations and financial condition; fluctuations in our operating results; risks related to investment in properties; risks relating to access to capital and credit markets to finance our present and future operations and business initiatives and obtain funding for such activities on favorable terms; risks related to indebtedness; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate and obligations in various jurisdictions in which we are subject to taxation; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure

We use, and expect in the future to use, o ur investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-), and the Biogen X account (x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and webcasts, as the information posted on them could be material to investors.

###⁶⁷

TABLE 1

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.